These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 26843061)

  • 1. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    BMC Med; 2016 Feb; 14():10. PubMed ID: 26843061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    Drug Saf; 2017 May; 40(5):431-441. PubMed ID: 28238125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    BMC Med; 2015 Feb; 13():26. PubMed ID: 25651859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    Crit Rev Toxicol; 2016 Jul; 46(6):477-89. PubMed ID: 26941185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    BMC Med; 2016 Nov; 14(1):191. PubMed ID: 27894343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1328-1337. PubMed ID: 28691251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Withdrawal Due to Safety: A Review of the Data Supporting Withdrawal Decision.
    Craveiro NS; Lopes BS; Tomás L; Almeida SF
    Curr Drug Saf; 2020; 15(1):4-12. PubMed ID: 31584381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.
    Pageot C; Bezin J; Smith A; Arnaud M; Salvo F; Haramburu F; Bégaud B; Pariente A;
    Drug Saf; 2017 Nov; 40(11):1099-1107. PubMed ID: 28664354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug safety: withdrawn medications are only part of the picture.
    Rawson NS
    BMC Med; 2016 Feb; 14():28. PubMed ID: 26873482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-marketing drug withdrawals: Pharmacovigilance success, regulatory problems.
    Aronson JK
    Therapie; 2017 Oct; 72(5):555-561. PubMed ID: 28461037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making.
    McNaughton R; Huet G; Shakir S
    BMJ Open; 2014 Jan; 4(1):e004221. PubMed ID: 24435895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    Expert Opin Drug Saf; 2018 Jan; 17(1):63-72. PubMed ID: 29076385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012.
    Lane S; Lynn E; Shakir S
    BMJ Open; 2018 Jan; 8(1):e019759. PubMed ID: 29362275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals.
    Arnaiz JA; Carné X; Riba N; Codina C; Ribas J; Trilla A
    Eur J Clin Pharmacol; 2001 Apr; 57(1):89-91. PubMed ID: 11372600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety-Related Drug Withdrawals in China Between 1999 and 2021: A Systematic Investigation and Analysis.
    Li Y; Jiang Y; Wang H; Zhang L; Yang Y
    Drug Saf; 2022 Jul; 45(7):737-745. PubMed ID: 35821561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase.
    Star K; Norén GN; Nordin K; Edwards IR
    Drug Saf; 2011 May; 34(5):415-28. PubMed ID: 21513364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons.
    Mendes D; Alves C; Batel Marques F
    Expert Opin Drug Saf; 2016 Oct; 15(10):1301-12. PubMed ID: 27467204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of paediatric studies of adverse drug reactions from pharmacovigilance databases.
    Cliff-Eribo KO; Sammons H; Choonara I
    Expert Opin Drug Saf; 2016 Oct; 15(10):1321-8. PubMed ID: 27501085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WITHDRAWN--a resource for withdrawn and discontinued drugs.
    Siramshetty VB; Nickel J; Omieczynski C; Gohlke BO; Drwal MN; Preissner R
    Nucleic Acids Res; 2016 Jan; 44(D1):D1080-6. PubMed ID: 26553801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.